• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 中国高校优秀期刊
  • 安徽省优秀科技期刊
YANG Shan, WANG Qing-yin. Analysis of the risk factors of epilepsy recurrence after stopping drug in patients treated with monotherapy[J]. Journal of Bengbu Medical University, 2017, 42(2): 198-200. DOI: 10.13898/j.cnki.issn.1000-2200.2017.02.019
Citation: YANG Shan, WANG Qing-yin. Analysis of the risk factors of epilepsy recurrence after stopping drug in patients treated with monotherapy[J]. Journal of Bengbu Medical University, 2017, 42(2): 198-200. DOI: 10.13898/j.cnki.issn.1000-2200.2017.02.019

Analysis of the risk factors of epilepsy recurrence after stopping drug in patients treated with monotherapy

More Information
  • Received Date: July 07, 2016
  • Objective:To analyze the epilepsy recurrence within 1 year after stopping drug in complete control patients treated with monotherapy,and high risk factors of inducing relapse.Methods:The drug was stopped in 130 epilepsy patients with monotherapy after the disease was completely controlled.The patients were followed up at least 1 year after stopping drug,and the epilepsy recurrence was recorded.Results:The recurrence rate within 1 year after stopping drug was 40.00%(52/130) in 130 epilepsy patients treated with monotherapy.The univariate analysis showed that the epileptic seizure was more than 5 times 1 year,the duration was more than 1 year before treatment,and the status epilepticus and intracranial lesions during the disease,epileptic discharge before stopping drug,no-attack time less than 4 years before reducing and stopping drug,high epilepsy relapse rate after stopping drug in patients with reducing drug time less than 6 months were found(P < 0.05 to P < 0.01).Multivariate logistic regression analysis showed that the epileptic seizure more than 5 times 1 year,duration more than 1 year before treatment,intracranial lesions,epileptic discharge before stopping drug,no-attack time less than 4 years before stopping and reducing drug time less,and reducing drug time less than 6 months were the high risk factors of epilepsy relapse(OR=2.976 to 8.742,P<0.05).Conclusions:The risk factors of the epilepsy recurrence in patients treated with monotherapy after stopping drug are more,taking appropriate intervention measures can reduce the recurrence of epilepsy.
  • [1]
    黄彦思,林云宾,冯婉萍,等.癫痫儿童智能和适应能力分析及抗癫痫药物治疗的影响[J].河北医学,2015,21(8):1390.
    [2]
    王馨.托吡酯与左乙拉西坦单药治疗癫痫患儿的疗效及安全性分析[J].安徽医药,2014,18(6):1162.
    [3]
    李维,周东.癫痫撤药相关问题[J].中国神经精神疾病杂志,2013,39(6):382.
    [4] 陶哲,伊文霞,韩颖,等.儿童癫痫发作的远期预后及相关因素[J].北京大学学报(医学版),2014,46(2):315.
    [5]
    许飞,孙红斌.单药治疗癫痫患者停药后复发的高危因素研究[J].中华神经医学杂志,2014,13(10):1053.
    [6]
    VERROTTI A,D'EGIDIO C,AGOSTINELLI S,et al.Antiepileptic drug withdrawal in childhood epilepsy:what are the risk factors associated with seizure relapse[J].Eur J Paediatr Neurol,2012,16(6):599.
    [7]
    BRAUN KP,SCHMIDT D.Stopping antiepileptic drugs in seizure-free[J].Curr Opin Neurol,2014,27(2):219.
    [8]
    杨琳,黄绍平.儿童难治性癫痫抗癫痫药物治疗策略[J].中国实用儿科杂志,2016,31(1):5.
    [9]
    周铨,侯小兵,黄志民,等.视频脑电图术前评估抗癫痫药物缓慢撤药方案的有效性和安全性[J].南方医科大学学报,2012,32(8):1197.
    [10]
    李娜,宋玉成.临床下痫样放电对癫痫患者认知功能及胰岛素样生长因子1水平的影响[J/CD].中华脑科疾病与康复杂志(电子版):2015,5(4

    ):218.
    [11]
    唐兴华,吴洵昳,师云波,等.229例癫痫无发作2年以上患者的脑电图特点及影响因素[J].中国临床神经科学,2013,21(2):160.
    [12]
    时新艳.全面惊厥性癫痫持续状态患者初始治疗失败的相关因素分析[J].中国实用神经疾病杂志,2014,17(14):77.
  • Cited by

    Periodical cited type(11)

    1. 包雪梅,张剑. 恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析. International Infections Diseases(Electronic Edition). 2020(01): 106 .
    2. 杨轲勇. 恩替卡韦对慢性乙型肝炎病毒感染患者HBeAg、HBV-DNA、ALT水平的影响. 临床医学工程. 2020(05): 639-640 .
    3. 夏培华,刘丽凤,于姜标. 苦参素联合抗病毒治疗慢性乙型肝炎肝硬化的效果观察. 中国药物与临床. 2020(05): 762-764 .
    4. 崔璐,蔡秋娥,王淼,王素华. 妊娠期乙肝患者服用替诺福韦后阻断宫内乙肝病毒传播疗效及安全性. 中国计划生育学杂志. 2020(10): 1658-1660 .
    5. 黄修伙,罗贤鑫,陈兴. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎的临床效果. 中国当代医药. 2020(31): 53-55 .
    6. 庄海珍,林丽华. 双环醇片联合恩替卡韦对慢性乙型肝炎患者血清乙型肝炎病毒表面抗原丙氨酸转氨酶水平的影响. 中国药物与临床. 2019(06): 963-966 .
    7. 刘飞飞,舒福丽,邬碧波. 恩替卡韦治疗慢性乙型肝炎病毒感染对患者HBV-DNA水平的影响及安全性观察. 临床合理用药杂志. 2019(19): 53-54 .
    8. 俞建家. 恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效研究. 实用心脑肺血管病杂志. 2019(S2): 93-94 .
    9. 陈晨楠. 恩替卡韦治疗HBeAg阴性代偿期慢性乙型肝炎肝硬化的临床效果观察. 现代医学与健康研究电子杂志. 2018(14): 38 .
    10. 梁洁玲,唐岚. 恩替卡韦对乙型肝炎病毒感染患者的临床疗效及其对肝功能的改善和HBeAg转阴的影响. 抗感染药学. 2018(09): 1587-1589 .
    11. 曹素珍. 恩替卡韦抗乙型肝炎病毒应答不佳患者挽救方案的效果对比分析. 临床医药文献电子杂志. 2018(90): 60+62 .

    Other cited types(0)

Catalog

    Article views (3514) PDF downloads (73) Cited by(11)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return